Clinical Trial Update: Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1. [Phase 1]

View source ↗

Summary

Phase 1 expansion cohort study of Bapotulimab (BAY1905254) in combination with pembrolizumab in PD-L1–expressing head and neck squamous cell carcinoma. The tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Bapotulimab (bapotulimab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Bayer | Conditions: Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: COMPLETED